Ralph Mazitschek

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U.

Blood Cancer J. 2023 Feb 07. 13(1):24. PMID: 36746923

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U.

Blood Cancer J. 2023 01 12. 13(1):12. PMID: 36631435

Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance.

Tye MA, Payne NC, Johansson C, Singh K, Santos SA, Fagbami L, Pant A, Sylvester K, Luth MR, Marques S, Whitman M, Mota MM, Winzeler EA, Lukens AK, Derbyshire ER, Oppermann U, Wirth DF, Mazitschek R.

Nat Commun. 2022 08 25. 13(1):4976. PMID: 36008486

A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader.

Payne NC, Maksoud S, Tannous BA, Mazitschek R.

Cell Chem Biol. 2022 08 18. 29(8):1333-1340.e5. PMID: 35649410

Resolving the deceptive isoform and complex selectivity of HDAC1/2 inhibitors.

Payne NC, Mazitschek R.

Cell Chem Biol. 2022 07 21. 29(7):1140-1152.e5. PMID: 35298895

Stereodivergent Complexity-to-Diversity Strategy en Route to the Synthesis of Nature-Inspired Skeleta.

Srinivasulu V, Srikanth G, Khanfar MA, Abu-Yousef IA, Majdalawieh AF, Mazitschek R, Setty SC, Sebastian A, Al-Tel TH.

J Org Chem. 2022 01 21. 87(2):1377-1397. PMID: 35014258

Bright and stable luminescent probes for target engagement profiling in live cells.

Payne NC, Kalyakina AS, Singh K, Tye MA, Mazitschek R.

Nat Chem Biol. 2021 11. 17(11):1168-1177. PMID: 34675420

Zinc-dependent histone deacetylases drive neutrophil extracellular trap formation and potentiate local and systemic inflammation.

Poli V, Pui-Yan Ma V, Di Gioia M, Broggi A, Benamar M, Chen Q, Mazitschek R, Haggarty SJ, Chatila TA, Karp JM, Zanoni I.

iScience. 2021 Nov 19. 24(11):103256. PMID: 34761180

Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC.

Oncotarget. 2021 Aug 17. 12(17):1736. PMID: 34434504

Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.

El-Awady R, Saleh E, Hamoudi R, Ramadan WS, Mazitschek R, Nael MA, Elokely KM, Abou-Gharbia M, Childers WE, Srinivasulu V, Aloum L, Menon V, Al-Tel TH.

Bioorg Med Chem. 2021 07 15. 42:116251. PMID: 34116381